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Ribonucleic acid (RNA) in its many facets of structure and function is becoming more fully understood, and, therefore, it is possible to design
and use RNAs as valuable tools in molecular biology and medicine. Understanding of the role of RNAs within the cell has changed dramati-
cally during the past few years. Therapeutic strategies based on non-coding regulatory RNAs include RNA interference (RNAi) for the silen-
cing of speciﬁc genes, and microRNA (miRNA) modulations to alter complex gene expression patterns. Recent progress has allowed the
targeting of therapeutic RNAi to the heart for the treatment of heart failure, and we discuss current strategies in this ﬁeld. Owing to
the peculiar biochemical properties of small RNA molecules, the actual therapeutic translation of ﬁndings in vitro or in cell cultures is
more demanding than with small molecule drugs or proteins. The critical requirement for animal studies after pre-testing of RNAi tools
in vitro likewise applies for miRNA modulations, which also have complex consequences for the recipient that are dependent on stability
and distribution of the RNA tools. Problems in the ﬁeld that are not yet fully solved are the prediction of targets and speciﬁcity of the
RNA tools as well as their tissue-speciﬁc and regulatable expression. We discuss analogies and differences between regulatory RNA
therapy and classical gene therapy, since recent breakthroughs in vector technology are of importance for both. Recent years have witnessed
parallel progress in the ﬁelds of gene-based and regulatory RNA-based therapies that are likely to signiﬁcantly expand the cardiovascular
therapeutic repertoire within the next decade.
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1. Introduction
The need to develop novel strategies for the treatment of heart failure
(HF) arises from the limited efﬁcacy of current therapeutic
approaches
1 for this serious disorder, which has a high and still
rising prevalence.
2 HF may result from multiple cardiac diseases
including myocardial infarction and genetic or exogenous cardiomyo-
pathies. Drug-based and surgical approaches including heart transplan-
tation (HTX)
3 and assist devices [left ventricular assist device
(LVAD)]
4 have signiﬁcantly improved the quality of life and prognosis
of HF patients. However, LVAD and HTX are available only for a very
small fraction of HF patients worldwide, and drug therapy has limited
efﬁcacy in advanced stages. Current novel approaches to HF treat-
ment include cell transfer-based therapies
5 and recombinant protein-
based approaches.
6–9 We focus here on treatment strategies based
on regulatory ribonucleic acid (RNA) or gene transfer to the heart.
For several therapeutic targets of major interest, inhibitory or enhan-
cing small molecule drug development has failed, and recombinant
protein substitution was not feasible due to intracellular or membrane
localization of the target. One recent prominent example is the
important regulator of cardiac contractility, phospholamban (PLB),
for which no inhibitory drug or antibody has been developed,
despite considerable efforts. Speciﬁcally, for ‘hard’ targets of this
type, which are not accessible by conventional pharmaceutical
agents, regulatory RNA- or gene-based therapy should be considered
as an alternative. It may be anticipated that therapeutically successful
target protein enhancement by gene transfer, or target protein sup-
pression by RNAi, will subsequently trigger research in conventional
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established therapeutic target.
2. Regulatory RNA- vs. gene-based
therapies
2.1 RNA world
The structure and function of RNA is becoming better understood,
and it is possible to design and use RNA molecules as valuable tools
in molecular biology and medicine. An understanding of the role of
RNAs within the cell has fundamentally changed during recent
years
10 (Figure 1). Its status expanded with reports on catalytic RNAs
(ribozymes) 25 years ago, of endogenous RNAi 15 years later, and
other non-coding RNA very recently. Today, it is obvious that RNAs
are not merely the intermediary molecules between DNA and pro-
teins, but thattheycan also be functional endproducts. Large stretches
of genomic DNA do not contain protein-coding sequences and have,
therefore, been considered as ‘junk’. However, a signiﬁcant fraction
of this non-coding DNA has actually been found to hold the infor-
mationforsomeofthesefunctionalnon-codingRNAs.Diverseeukary-
otic organisms harbour a class of non-coding small RNAs which are
thought to function as regulators of gene expression. Thus, RNAs
can be the transmitters [messenger RNAs (mRNAs)] of genetic infor-
mationtotheribosomeforproteinstobesynthesized,andalsothereg-
ulators in protein synthesis. The conclusion to be drawn is that RNA is
muchmorethansolelyanmRNA,and,therefore,moleculesofthisclass
are truly renaissance molecules.
RNA has become a focus of investigations into novel therapeutic
schemes. Ribozymes, antisense RNAs (asRNAs), RNA decoys, apta-
mers and spiegelmers,
11,12 microRNAs (miRNAs), and small interfer-
ing (siRNAs) have been used to down-regulate undesired gene
expression (Figure 2). Multiple challenges, such as optimization of
selectivity, stability, delivery, and long-term safety, have to be
addressed in order for ‘RNA drugs’ to become successful therapeutic
agents. The recognition of the biological roles of small molecular
weight RNAs have been one of the most signiﬁcant discoveries in
molecular biology. These RNA molecules inﬂuence the translation
of mRNAs in a post-transcriptional manner that makes the regulation
of RNAs even more complex. The use of RNA interference (RNAi)
mediated by siRNAs or short hairpin RNAs (shRNAs) for the silen-
cing of speciﬁc genes has provided a powerful tool for loss-of-function
studies. RNAi-mediated gene silencing by degradation of target
mRNAs has been widely used in gene function characterizations.
Compared with the very laborious, time-consuming, and costly gene
knockout models, RNAi may provide an efﬁcient, speciﬁc, and
cheap solution to inhibit target genes. However, efﬁcient RNAi deliv-
ery is essential for the success of speciﬁc gene silencing and difﬁcult to
achieve in vivo, in particular if silencing is desired only in one organ.
In several recent studies, microarray and other analyses were per-
formed to determine whether another class of small regulatory RNA
molecules designated as miRNAs are deregulated in cardiac diseases
diseases.
13–18 A major challenge for the future will be to identify
the targets of miRNAs that participate in the respective pathome-
chanisms and to understand their mechanistic contribution in detail.
This may be the most important threshold to pass before regulatory
agencies allow these RNA tools into the clinic. Finally, the recent
application of advanced vector technologies developed initially in
the classical gene therapy ﬁeld has had an enormous impact on the
efﬁcacy by which RNAi and miRNAs can be employed for therapeutic
purposes in vivo. These most recent developments have brought clini-
cal translation of certain RNA-based therapies within reach.
2.2 RNA interference
The discovery of co-suppression in Petunia plants about 18 years ago
turned out to be a foundation of the dynamically expanding
Figure 1 Traditional and current concept for coding vs. non-coding DNA functions. Only a small fraction of the RNA species found in eukaryotic
cells has protein-coding function, the traditional role for RNA. During the past decade, a multitude of RNAs arising from the huge non-coding part of
the genome was discovered to exert regulatory functions of fundamental importance to maintain normal cell function.
W. Poller et al. 354technology of RNAi, with scientiﬁc and medical impact comparable to
the discovery of polymerase chain reaction or mouse knockout tech-
nology.
10 That original discovery revealed that introduction of double-
stranded RNA (dsRNA) into a cell can trigger a target sequence-
speciﬁc gene-silencing mechanism.
19 Within the cell, the dsRNA is
processed in short  22 nt-long fragments by an evolutionary
ancient, endogenous machinery later designated as RNAi. It was
later discovered that the silencing effect of dsRNA may be mimicked
by chemically synthesized siRNA.
20 The challenge to produce siRNAs
in vivo was met by designing vectors expressing shRNAs from RNA
polymerase III promoters (U6, H1, and 7SK), which were in cells pro-
cessed into active siRNAs. In parallel with the study of RNAi, progress
in understanding the cellular processing and function of miRNAs was
achieved. RNAi and miRNA systems share most components of the
silencing pathway (Figure 3). Theoretical predictors for efﬁcient and
target-speciﬁc silencing RNA sequences have been incorporated in
numerous dedicated software, but still always need to be veriﬁed
ﬁrst in the relevant target cells and ﬁnally in respective animal
models in vivo. Ideally, an RNAi tool will silence one single gene
without any ‘off-target’ effects.
2.3 MicroRNAs
In computer science, ‘macro’ describes a single command pro-
grammed to replace multiple separate commands performing a
series of actions, thus simplifying, expediting, and minimizing error.
By analogy, living cells may employ a single miRNA to modulate the
expression pattern of a whole group of genes that coordinate a par-
ticular cell function. Regulation of multiple genes by a single miRNA
obviates the need for transcriptional regulation of individual genes
and facilitates synchronization of the regulatory effects and prompt-
ness of the response. miRNA are targets of signiﬁcant therapeutic
interest. In advance of therapeutic targeting of an miRNA, however,
detailed knowledge of its gene targets, functions, and tissue
distribution are required. Since mammalian miRNA research is still
in an early phase, informations in that regard are as yet incomplete.
Nevertheless, certain miRNA targets with major therapeutic rel-
evance for cardiovascular diseases have already been well character-
ized and investigated in animal models.
13–15,17,18,21,22
Therapeutic miRNA modulations may be classiﬁed into inhibition of
a speciﬁc miRNA or overexpression of an miRNA in the target cells
(Figure 3). In contrast to RNAi which is intended to serve ideally as a
single-target silencing tool, miRNA modulations are a priori intended
to address multiple targets. Commonly but not always,
23 an miRNA
silences gene expression by binding to complementary mRNA
sequences in the 3′-untranslated regions (UTRs) of their target
genes. Up-regulation of protein expression by miRNA binding to
the 5′-UTR has also been described, so that miRNA overexpression
does not necessarily results only in silencing of the target genes.
Therefore, both inhibition and overexpression of a single miRNA
are likely to have complex ramiﬁcations for the function of the
treated cells. As outlined in the left of Figure 3, miRNA inhibition
has been achieved by ‘antagomirs’,
24 anti-microRNA oligodeoxyribo-
nucleotides,
25 miRNA ‘target masking’ that blocks miRNA binding,
26
and ‘sponges’
27 or ‘erasers’
28 both of which act by scavenging
miRNAs. Targeting of these RNA tools is commonly dependent on
expression from a vector with appropriate tropism, whereas the
antagomir approach instead attempts to achieve this goal by direct
coupling of the RNA tool itself to a targeting ligand. The ﬁrst antag-
omirs employed an miRNA-speciﬁc, anti-sense, cholesteryl-
conjugated, 2′-O-methyl oligoribonucleotide which is cell permeable
and inhibits the miRNA by inducing its elimination. Interestingly, it
offers a relatively long-lived effect and for certain applications, circum-
vents the need for a speciﬁc delivery vehicle such as an organotropic
viral vector. Pioneering work on antagomir-based ablation of the
HF-associated miRNA-21 overexpression in cardioﬁbroblasts has
shown impressive therapeutic potential, although this miRNA is
expressed in multiple tissues and intravenously injected antagomir
enters most organs except the brain. Since no side effects in non-
cardiac organs were observed, it is obviously not mandatory to
achieve targeting of an ‘RNA drug’ exclusively to the diseased
organ.
29 It will be interesting to see which other diseases may be efﬁ-
ciently treated by this ‘untargeted’ and elegant approach without sig-
niﬁcant side effects.
The replenishment of depleted miRNAs or their deliberate overex-
pression with therapeutic intention, on the other hand, requires the
delivery of the premature miRNA (pre-miRNA) in its native form
(Figure 3) in order to allow proper processing and incorporation
into the RISC complex. For this group of strategies, other delivery
methods similar to those employed in classical gene therapy are
needed, but important additional restriction has to be met if small
RNA molecules are to be generated.
30 Pioneering studies in the
cancer ﬁeld have described impressive therapeutic effects by overex-
pression of miRNA-206
31 and miRNA-205,
32 whereas to our knowl-
edge, analogous therapeutic miRNA overexpression has not yet been
employed for cardiovascular diseases.
Although major progress is being made in deciphering the molecu-
lar foundations of RNAi, e.g. by solving the structure of an argonaute
silencing complex,
33 reliable prediction of RNA sequences with high
and speciﬁc silencing capacity for single genes (by RNAi) or miRNA
(e.g. by antagomirs) by calculation alone is not yet possible and
sequences and constructs have always to be validated in the relevant
experimental models in vivo.
Figure 2 RNA-based technologies for gene and protein silencing.
A broad spectrum of ‘tools’ made from RNA molecules has been
developed that are capable of either suppressing speciﬁc gene/
protein functions or of altering complex expression patterns
(miRNAs). By these capacities, RNA tools signiﬁcantly extend the
therapeutic repertoire beyond that of classical pharmacology.
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and gene therapy
The classical concept of gene therapy which has been developed for
monogenic disorders caused by deﬁciency of a single gene is gene
substitution therapy. In the ﬁeld of cardiology, several monogenic dis-
orders manifested in the myocardium could theoretically be cured by
this approach. Among them are long-QT syndromes, arrhythmogenic
right ventricular dysplasia, Brugada syndromes, hypertrophic cardio-
myopathies caused by a host of mutations in sarcomeric proteins,
and dilated cardiomyopathies. A second concept is the enhancement
of gene functions by overexpression of primarily endogenous genes
using gene transfer. Under appropriate conditions, a therapeutic
effect may be achieved not only in genetically determined but also
in acquired diseases. A third concept is the addition of truly novel
gene functions to the target organ by vector-based expression of
foreign genes. Novel concepts of far more recent origin involve the
use of non-coding, small regulatory RNA molecules for therapeutic
purposes. They include the concept of shRNA transcription for the
suppression of gene functions in the diseased organ by the mechanism
of RNAi, and the concept of pre-miRNA generation to achieve modu-
lation of cell functions on the level of the cellular miRNA systems.
Naturally, all key issues of classical gene therapy apply similarly to
the RNA-based therapies. Figure 4 illustrates some fundamental
differences between gene and regulatory RNA therapies, but at the
same time points to signiﬁcant methodological overlaps between
these distinct strategies. Common to both is the need to deliver
the therapeutic tool (cDNA or regulatory RNA) to the right place,
at appropriate concentration for a sufﬁcient period of time, and
with adequate safety features. This allows researchers to employ
advanced vector technologies, initially developed in the gene
therapy ﬁeld, also for several types of RNA therapy.
2.5 Technical challenges common
to regulatory RNA and gene therapy
2.5.1 Targeting of the tools
A key issue of vector technology is the physical steering (targeting) of
the vector (expressing a protein-coding cDNA, shRNA, or pre-
miRNA) to the target tissue. Cardiac targeting proved to be an extre-
mely difﬁcult task that could not be solved in a simple and efﬁcient
way using earlier gene transfer systems. A breakthrough in the ﬁeld
has been achieved with the introduction of adeno-associated virus
(AAV) vector systems,
34–38 in particular the discovery of highly cardi-
otropic AAV serotypes
39–41 and the reengineering of AAV with thera-
peutically desirable properties.
35,38 This has not only led to successful
gene therapy
42–45 and recently also regulatory RNA therapy
30 in vivo
by direct intravenous injection in animal models, but is already in the
Figure 3 Current strategies for regulatory RNA modulation. The cartoon outlines the principle of RNAi alongside that of miRNA enhancement,
both of which share multiple cellular components (boxes on the right), as well as strategies towards miRNA inhibition (left).
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46 If perfect targeting cannot be
achieved (transductional targeting), further transcriptional conﬁne-
ment of the transgene may be achieved by using cardiac-speciﬁc pro-
motors. It should be emphasized that the novel generation of
cardiotropic AAV vectors is distinct from previous systems not only
by cellular receptor afﬁnity (resulting from virion surface properties),
but even more importantly by their ability to overcome key anatom-
ical barriers on their way to the heart (endothelium, basal membrane,
and extracellular matrix) by some as yet unidentiﬁed mechanism (e.g.
transmigration through the endothelium). Their practical application is
therefore far more simple than former approaches employing sophis-
ticated catheter delivery and endothelium-permeabilizing drugs.
47–49
2.5.2 Stability and regulation of the tools
A second key issue of vector technology is the stability of therapeutic
tool (cDNA, shRNA, and pre-miRNA). Small regulatory RNAs are
inherently unstable, and viral vectors are currently the only tools
for non-topical in vivo therapy using these molecules. On the other
hand, multiple proteins are also inherently unstable and/or intracellu-
lar, which likewise suggest the use of long-term stable vectors for
long-term therapy. If RNA- or gene-based therapy for HF is not
only meant to serve as bridge-to-transplant or bridge-to-recovery,
then long-term persistence and functionality of the therapeutic
vector is required. The high stability appears to be a consequence
of inherent fundamental biological properties of the AAV genome.
AAV vectors have developed into the vectors of choice for the treat-
ment of HF,
30,48,50 cardiac storage as in Fabry disease,
51 and gene sub-
stitution as in d-sarcoglycan deﬁciency,
52 with transgene expression
over several months in all cases.
In contrast to therapy of viral infections where complete inhibition
of viral gene expression is desirable, for many cardiac disorders, suc-
cessful therapy would require the regulation of gene expression levels
within a narrow therapeutic window to avoid side effects. RNAi-
mediated ablation of PLB which plays a key role in the regulation of
cardiac Ca
2+-homeostasis showed high therapeutic potential in HF
animal models. However, humans lacking functional PLB due to
genomic mutations developed lethal cardiomyopathy
53 so that unre-
gulated long-term inhibition of PLB by RNAi may therefore be of
potential risk in humans, despite successful application in rodents.
RNAi may also exert serious side effects in vivo under adverse circum-
stances.
54,55 A mode to switch on/off shRNA expression in thera-
peutic settings is therefore highly desirable before application in
man. The basis for regulatable RNAi to date is a panel of
drug-inducible gene expression systems where a drug-dependent
transactivator and transrepressor protein activates and suppresses a
responsive promoter and transcription, respectively. Regulatable ‘on’
system seems to be more suitable than ‘off’ systems for therapy
since here transgene expression is induced by drug application and
simply switched off by withdrawal of the drug (further details in
Poller et al.
56).
2.5.3 Safety issues
A third key issue of vector technology, of paramount importance
before any clinical application, is the safety of the therapeutic tools
which is determined by the properties of the regulatory RNA only,
if it is applied as a synthetic molecule, or in addition by those of
the delivery vehicle in the case of vector-based RNA therapies. As
depicted in Figure 3, toxicity of an shRNA may arise from competition
Figure 4 RNA and gene therapy—relation to other therapeutic concepts. Regulatory RNA- and gene-based strategies have recently been success-
fully used for cardiac therapies in vivo. Recent developments in vector technology laid the foundation for efﬁcient, cardiac-targeted, and stable RNA
and gene delivery. Parallel evolution of RNA technology enabled stable expression of RNAi-mediating small RNAs over months. A fully synthetic class
of RNA molecules, spiegelmers, displays high stability in vivo and constitutes a novel class of RNA drugs with signiﬁcant therapeutic potential. Only in
selected cases, these fundamentally new approaches may be replaced by conventional drugs or proteins.
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icity arising from this mechanism has been described,
54 but could be
overcome by selecting alternative non-toxic shRNA sequences and
appropriate dose.
55,57 For other target diseases approached by the
use of cardiotropic RNAi vectors with low afﬁnity to the liver,
30 no
hepatic or other toxicity was observed, but certainly always needs
to be taken into consideration. Off-target effects of regulatory
RNAs are another possible source of toxicity and difﬁcult to assess.
Microarray studies may analyse genomic expression pattern changes
induced by an siRNA or shRNA, but even for these single-target
tools, multiple changes will arise secondary to the silencing of the
single intended gene. Essentially useless is this approach if unwanted
miRNA effects are to be identiﬁed, since miRNA modulation will a
priori result in complex expression pattern changes. As a conse-
quence, side effects at the cellular level and in vivo need to be inves-
tigated to assess possible toxicity of the RNA drugs.
Their delivery system is another issue of concern. We focus here
on AAV vectors and derived biological nanoparticles (BNPs) since
their safety proﬁle is superior to the formerly used adenoviral, retro-
viral, and lentiviral vectors. Beyond regulation of the transgene to
adapt expression to the actual needs of the patient, an option to
shut down the transgene at any time in the case of serious adverse
effects is highly desirable under safety aspects. Adenoviral vectors
are associated with several safety issues likely to prevent their clinical
application for non-malignant diseases, given the availability of natu-
rally occurring or engineered AAVs with signiﬁcantly more favourable
safety proﬁles. Their immunogenicity is very low compared with ade-
novectors, although not absent.
58–60 Another possible risk has been
deduced from the capacity of wild-type AAV for chromosomal inte-
gration which is fortunately lost, however, in recombinant AAV
vectors. Chromosomal effects of integration deserve attention after
a report on late occurrence of leukaemia in children treated with ret-
roviral vectors for severe combined immunodeﬁciency, after success-
ful correction of the primary genetic defect.
61 The development of
non-invasive methods for vector tracking in vivo is also desirable as
an additional safety and control feature, but has not yet been achieved
at the required sensitivity.
3. Regulatory RNA and gene
therapies in cardiology
3.1 Two classes of therapeutic targets
HF remains a leading cause of mortality in the developed world.
During the past few years, a several molecular targets have been
identiﬁed and investigated in animal models (and in one case in
humans) to improve the deteriorated function of the failing heart.
Several therapeutic targets are relatively independent of the speciﬁc
origin of HF, and therefore deserve particular clinical interest due
to the large number of patients which may in principle proﬁt from
modulations of those targets. The cartoon of Figure 5 distinguishes
groups of targets that fall into two distinct classes, one of which
(‘Class A’) needs to be enhanced, whereas the other one (‘Class B’)
needs to be suppressed for therapeutic purposes. Groups 1–4 are
well documented to be altered in HF of diverse aetiologies: (1)
myocardial Ca
2+ and Na
+ homeostasis
30,42,62–64 (for details, see
paragraph below), (2) b-adrenergic signal transduction,
37,45,65 (3)
extracellular matrix remodelling,
66,67 and (4) innate immune
signalling.
68,69 Recent investigations suggest that targets associated
with immune cell trafﬁcking and cardiac immune cell inﬁltration
(Group 5) are also altered across a spectrum of cardiac disorders
beyond the classical viral/autoimmune pathology.
70–78 In contrast,
narrowly speciﬁc therapeutic targets are found in monogenic (Fabry
disease,
51 d-sarcoglycan deﬁciency,
44,52 and others
49,72 (Group 6)
and virus-induced cardiomyopathies
79–81 (Group 7).
Excellent recent reviews have described several aspects of gene
therapy for cardiac diseases. We therefore focus here on the funda-
mentally novel approach of therapies employing regulatory RNA mol-
ecules for that purpose, and on the most recent developments for the
cardiac delivery of both regulatory RNA molecules and genes. The
Figure 5 Spectrum of targets for heart failure therapy. The cartoon distinguishes two different classes of targets that need to be approached by
using fundamentally distinct methods. ‘Class A’ targets (green) need to be enhanced for therapeutic purposes, whereas ‘Class B’ targets (red) require
suppression. Only a fraction of the currently known targets is listed for illustration. “General” denotes therapeutic targets relevant to HF of any origin,
whereas “speciﬁc” targets are relevant for speciﬁc etiologies only.
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safety of the therapeutic tools apply to all the targets summarized
in Figure 5. Until the discovery of induced RNAi for gene silencing
and consecutive protein ablation, Class B targets were only accessible
by drugs or antibodies. As a ﬁrst successful example of this new RNAi
approach for a Class B target, we describe below PLB silencing to
treat HF. As evident from Figure 5, however, a multitude of other
Class B targets has already been identiﬁed and may be approached
by RNAi silencing the speciﬁc gene only that expresses the Class B
target protein. Other RNA therapeutic technologies involving
miRNA ablation and silencing of multiple targets by a single tool are
summarized in Figure 3 and have already been discussed in above para-
graph ‘miRNAs’. Clinical translation of RNAi is a demanding challenge,
but is likely to fundamentally expand the therapeutic repertoire for
cardiovascular diseases during the next decades.
82
3.2 RNAi: a novel approach towards
Class B targets
For long-term treatment of HF, novel approaches are currently being
explored, including gene and cell therapies
5 and recombinant protein-
based approaches
6–9 and combinations thereof,
83 whereas the use of
RNAi to modulate cardiac functions had not yet been evaluated. As
ﬁrst successful example of this new RNAi approach for a Class B
target, we describe PLB silencing to treat HF. Whereas gene
therapy rests on recombinant protein expression as its basic principle,
RNAi therapy instead uses small regulatory RNAs to achieve its effect.
Targeting, kinetics, and toxicity of these RNAs in vivo are grossly
different from those of recombinant proteins.
10,55,82,84,85 HF may
result from multiple causes, but defective cardiac Ca
2+ homeostasis
is an import ﬁnal common pathway. We recently demonstrated treat-
ment of HF by the use of a cardiac-targeted RNAi strategy addressing
PLB as a key regulator of cardiac Ca
2+ homeostasis. Cardiac malfunc-
tion is in part due to dysfunction of the PLB-controlled sarcoplasmic
reticulum Ca
2+ATPase pump (SERCA2a), as a consequence of
reduced SERCA2a expression or PLB phosphorylation. Unpho-
sphorylated PLB keeps the Ca
2+ afﬁnity of SERCA2a low, resulting
in decreased sarcoplasmic reticulum (SR) Ca
2+ uptake, slowed relax-
ation, and decreased SR Ca
2+ load. In contrast, PLB phosphorylation
in response to b-adrenergic stimulation relieves this inhibition.
62
Germline ablation of the PLB gene, gene transfer for dominant-
negative PLB mutants,
48,86 asRNAs,
87 and inhibitory antibodies
88
have been employed to enhance SERCA2a activity and rescue exper-
imental HF.
89 RNAi by synthetic siRNAs in cardiomyocytes displayed
very low efﬁcacy and stability even in vitro,
90 and pharmacological
approaches to PLB modulation have failed so far. Inherent limitations
of synthetic siRNAs are their very rapid degradation in plasma and
target cells, and the unsolved problem of in vivo delivery and tissue
targeting. Viral vectors have the potential to overcome these limit-
ations, and efﬁcient PLB ablation was achieved in cultured cardiomyo-
cytes [neonatal rat cardiomyocyte (NRCMs)] by the use of an
adenoviral RNAi vector.
91 No change in the expression of other
cardiac proteins, including Ca
2+ handling proteins, occurred indicating
high target speciﬁcity. On the basis of this in vitro work, we evaluated
the principle of RNAi against PLB for short- and long-term treatment
of HF in vivo. Functional characterization of a series of vectors and the
determinants of their efﬁcacy was required, before investigation of
both an optimized recombinant adeno-associated virus pseudotype
9 vector (rAAV9) alongside a traditional adenoviral vector in an
animal model of HF became possible.
Building upon landmark articles describing highly cardiotropic
vector systems,
39,40 we were able to achieve in vivo restoration of
cardiac function and reduction of pathological hypertrophy and
dilation in an HF animal model by RNAi. Comparison of the two
vector systems used suggested that for intermediate timescales,
adenoviral vectors may sufﬁce and even provide advantages over
long-term stable rAAVs,
38–40,92 because RNAi may be desirable
only temporarily in acute and potentially reversible HF. In fact, the
signiﬁcant improvement of diastolic and systolic function and LV
morphology 1 month after adenovirus (AdV)-shPLB treatment was
evidence of at least a functional therapeutic beneﬁt from the adeno-
viral system. What has been shown previously for classic gene transfer
therapy
42 may obviously work for RNAi-based strategies, too, but
strict additional constraints exist for RNAi vector structure to avoid
loss of therapeutic efﬁcacy and disturbance of miRNA pathways.
54,93
The experiments further suggest that rAAV-based RNAi may be suit-
able for the long-term treatment of chronic HF by RNAi strategies. In
classic gene therapy studies, rAAV vectors have supported stable
transgenic protein expression for more than 1 year, which was
never achieved with adenoviral systems in immunocompetent hosts.
Although shRNA production from rAAVs is different in several
aspects from classic gene transfer, the data from the rAAV arm of
the present study provided the ﬁrst evidence that cardiac rAAV9-
based shRNA production remains stable for a period of time sufﬁcient
for long-term improvement of cardiac function and possibly also sur-
vival in HF. The classical method for gene delivery by recombinant
AdV uses cross-clamping of the aorta and the pulmonary arteries in
rat hearts and yields homogeneous transgene expression.
47 In our
study, employing an advanced AAV vector developed from the
highly cardiotropic AAV9 serotype, ﬂuorescent imaging and immuno-
histochemistry showed that a single intravenous injection of an
rAAV9-GFP marker vector induces strong and grossly homogeneous
cardiac GFP expression 1 month after treatment (Figure 6).
The important observation that co-expression of GFP together
with shPLB extinguishes its silencing capacity currently prevents
direct demonstration of spatial and temporal uniformity of cardiac
shRNA synthesis in vivo by standard GFP co-expression. Uniformity
was deduced, however, by inference from analogous in vivo imaging
of GFP expression from adenoviral and rAAV9 vectors. With
rAAV9-GFP, the cardiac transduction rate increased over time and
reached 90% after 1 month. The improvement of HF by both RNAi
therapeutic protocols was mediated via ablation of PLB protein in cul-
tured NRCMs
91 and in rat hearts in vivo (Figure 6).
After RNAi therapy, cardiac SERCA2a expression was increased
compared with HF groups, consistent with the facts that RNAi
therapy normalized LV function, and that SERCA2a expression is a
marker of the degree of HF.
94 Both RNAi therapies induced a
decrease in cardiomyocyte size. Notably, AdV-based therapy over
1 month did not inﬂuence the ﬁbrosis induced in failing hearts,
whereas long-term rAAV9-based treatment resulted in signiﬁcantly
reduced ﬁbrosis after 3 months.
30
Irrespective of such subtle differences, however, the effect of the
RNAi vectors in vivo on PLB ablation, haemodynamics, and mor-
phology
30 conﬁrmed that the doses chosen for both systems are
within the therapeutic range. The AAV9 vector used in this study
fulﬁls one important requirement for application in human HF,
because it is cardiotropic in primates.
39 In addition to its long-term
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cardiac targeting after intravenous injection (Figure 6) and low immu-
nogenicity. In contrast to rodents, regulatable PLB modulation will
likely be required in humans, because permanent PLB deﬁciency or
PLB dysfunction due to genomic mutations has been linked to cardi-
omyopathies.
95,96 Drug-regulatable RNAi appears possible on both
vector platforms used in our study. However, transcriptional
control of shRNA expression is technically signiﬁcantly more demand-
ing than the use of the tissue-speciﬁc promoters employed for tra-
ditional gene therapy, as these promoters are unable to support
proper formation and cleavage of shRNA. New promoters compati-
ble with shRNA biosynthesis are still under development and may
add an additional safety feature to organ-targeted RNAi therapies.
3.3 Pathogenetic analyses employing
advanced RNA technology
Independent of its therapeutic potential, organ-targeted RNAi may
be of use to identify novel gene functions in that organ by functional
ablation, analogous to classic tissue-speciﬁc inducible knockout
Figure 6 Protocol for RNA interference therapy of heart failure (reproduced by permission from Suckau et al.).
30 (A) Animals for RNAi therapy
were divided into two groups: one of 56 animals with aortic banding and a second of 12 sham-operated animals. In aortic-banded animals, we waited
for them to develop LV dilatation and a decrease in fractional shortening by 25% before cardiac RNAi vector transfer. Of 56 aortic-banded animals, 40
survived and were divided into groups receiving AdV-shGFP, AdV-shPLB, rAAV9-shGFP, or rAAV9-shPLB. In the aortic root, 3 × 10
10 pfu of each AdV
was injected. For experiments with rAAV9, tail-vein injection was done with 5 × 10
11 genomes of either vector. Outcome evaluation by echocardio-
graphy, tip catheter, morphometry, and histology was performed after 1 month in the adenoviral and after 3 months in the rAAV9 groups (see ref.
30).
(B) Immunohistochemical staining of GFP in different organs 1 month after intravenous injection of rAAV9-GFP. Whereas after intravenous injection of
an adenoviral vector (AdV-GFP), no GFP was detected in the heart (a), rAAV9-GFP treatment resulted in strong GFP expression (b and c) which was
grossly homogeneous. An average of 70% of cardiomyocytes were positive by immunohistochemistry. (e) Skeletal muscle with faint staining of a frac-
tion of cells, whereas the liver shows prominent signal of individual cells only (d). No signal was visible in the lungs (f ). Few areas were completely
devoid of GFP immunoreactivity (encircled yellow areas); others showed homogeneous cytoplasmic staining (red circles). Staining was particularly
dense at sites where high expression over 1 month had obviously resulted in the formation of precipitates (white arrows) of GFP. (C) Rats were
injected intravenously with an rAAV9-GFP vector expressing GFP or with saline. One month later, GFP imaging showed a grossly homogeneous
cardiac GFP signal in the rAAV9-GFP group (bottom) and no signal in the saline group (top). (D) Representative western blots show a signiﬁcant
decrease in cardiac PLB protein after 1 month of AdV-shPLB and 3 months of rAAV9-shPLB therapy, compared with shGFP control groups. The
sodium–calcium exchanger and GAPDH protein remained unchanged. SERCA2a was decreased in the shGFP groups that were in HF compared
with sham, whereas SERCA2a was increased signiﬁcantly in both shPLB groups. *P , 0.05 compared with AdV-shGFP;
#P , 0.05 compared with
rAAV9-shGFP.
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sufﬁce to recognize unknown gene functions, and the efﬁcacy of
this novel analytical approach is likely to increase with the advent
of more sophisticated RNAi delivery systems. Importantly, gene
ablation by RNAi may be induced at any desired age or disease
state and would be more rapid and inexpensive than the traditional
models.
3.4 Consideration of side effects of RNAi
The cellular machinery of RNAi evolved over millions of years and is
the most efﬁcient and versatile mechanism known for speciﬁc gene
silencing. shRNAs exploit this machinery to mediate therapeutic
effects by mimicking the endogenous process and achieve silencing
at far lower concentrations than asRNAs, but they may disturb cellu-
lar miRNA pathways
54,55 and thereby cause hepatotoxicity. When
using a cardiotropic rAAV9 serotype with low afﬁnity for the liver,
we observed no histological evidence of acute or chronic liver
damage. We also studied the cardiac-expressed miRNAs 1 and 133
during RNAi treatment. Because malignant arrhythmias are important
complications in HF, deregulation of an arrhythmia-related miRNA
such as miRNA-1,
15 by a novel treatment, should be considered as
a possibly serious adverse effect. None of the RNAi vectors
changed miRNA-1 levels in NRCMs, but interestingly, shPLB treat-
ment was instead associated with rescue of the miRNA-1 depression
induced by phenylephrine in these cells, and rat hearts that underwent
shPLB therapy had higher miRNA levels than controls. In conjunction
with the trend towards improved survival in the AAV-shPLN
treatment group, no evidence was thus found for arrhythmogenic
side effects. Although improved contractile function during
shPLB therapy results immediately from its inﬂuence on excitation–
contraction coupling via the cytoplasmic Ca
2+ transients, the
marked reduction of LV hypertrophy and dilation is not deduced as
easily, because it involves major reprogramming of the cardiac tran-
scriptome. The RNAi-induced changes of Ca
2+ homeostasis may
affect not only the cytoplasmic Ca
2+ transients but also the separate
and insulated Ca
2+ signals generated in the perinuclear space
97,98 that
inﬂuence transcription. With respect to hypertrophy, it is of interest
that shPLB treatment was associated with rescue of the
phenylephrine-induced miRNA-133 depression in NRCMs and
higher levels in rat hearts on shPLB treatment. The rescue of
miRNA-133, which plays a critical role in the control of cardiomyo-
cyte size,
21,99 appears to be linked to RNAi at the cell level,
because it also occurs in vitro, where haemodynamic stress, neurohu-
moral, or cytokine activation, as in HF in vivo, cannot play any role.
Although our rationale to measure miRNA expression was to test
whether shPLB may ‘poison’ the RNAi machinery, differential
miRNA induction can also be viewed as ‘master switches’ that
control reinduction of foetal genes during HF.
14 A clear distinction
between side effect and master-switch aspects of miRNA regulation
is very difﬁcult and certainly beyond the scope of the present
report. In addition, clariﬁcation of the mechanism by which
shPLB-RNAi is linked to the changes in miRNA-1 and miRNA-133
(passive association or component of the therapeutic process)
requires future studies.
The investigation outlined above
30 provides a ﬁrst example for high
efﬁcacy of a locally targeted RNAi therapeutic strategy in a cardiac
disease. The paper emphasizes the critical need for careful vector
adaptation to the speciﬁc requirements of RNAi, and for extensive
characterization of candidate regulatory RNA sequences with
respect to high intrinsic activity and target speciﬁcity. Under these
preconditions, RNAi therapy may achieve long-term cardiac beneﬁt
without apparent toxicity. When functionally optimized RNAi
vectors were used, and aortic root vector injection or cardiotropic
rAAV9 capsids were used to target RNAi to the heart, no evidence
was found of side effects. Short-term PLB silencing led to improved
cardiac function 1 month after aortic root injection of an adenoviral
RNAi vector. Long-term RNAi after simple intravenous injection of
an optimized rAAV9 vector resulted in restored cardiac function
and reduction of cardiac dilation, hypertrophy, and ﬁbrosis after a
period of 3 months. The rAAV9 approach uses a vector known to
target the heart in primates,
39 thus offering potential for clinical trans-
lation. Speciﬁcally, for targets such as PLB in which pharmacological
approaches have failed thus far, the RNAi approach may enhance
the therapeutic repertoire for cardiac diseases. Multiple other Class
B targets (Figure 5) are likely to be investigated in the near future.
4. Translation issues and clinical
trials
With respect to the clinical translation of RNA therapeutic strategies,
it may be anticipated that some of them may ultimately be substituted
by more traditional ‘pharmacological’ approaches than the pioneering
studies which mostly employ highly sophisticated methods. One
important recent example is the use of an intravenously injected,
untargeted antagomir to ablate the HF-associated miRNA-21.
Whereas the landmark papers that have elucidated the biological
and pathogenic roles of this miRNA have used transgenic and knock-
out animals and viral vectors, the antagomir approach has shown
impressive therapeutic potential, although its target is expressed in
multiple organs.
29 It will be interesting to see which other diseases
may be efﬁciently treated by this ‘untargeted’ and elegant approach
without signiﬁcant side effects in non-target organ due to miRNA
depletion at these sites.
In contrast to this ‘pharmacological’ approach at miRNA ablation,
there was so far no successful in vivo therapeutic application of
RNAi based on synthetic siRNAs or chemical derivatives. The
reason for this is their still very short half-lifes in plasma and target
cells and the lack of proven concepts for organ targeting. In the
ﬁeld of RNAi therapy, the introduction of AAV vectors with favour-
able safety proﬁles has nevertheless allowed to use the powerful
approach of RNAi for successful therapy of both systemic
54 and
local diseases
30,81 in vivo. Such proof-of-concept studies have triggered
major interest in the pharmacological industry to investigate to what
extent these therapies may be mimicked by modiﬁed synthetic
siRNAs. Obviously, pharmacological approaches face the challenge
of delivering extremely unstable small RNAs, even if in some cases
targeting may not be required. Both stability and targeting may be
achieved by the use of advanced vector technologies
35,38 for both
gene therapy and regulatory RNA delivery. A ﬁrst clinical trial has
recently demonstrated the feasibility of a vector-based approach for
HF therapy by cardiac SERCA2a gene transfer in humans
46 and an
analogous RNAi therapeutic strategy has been successfully applied
in a rodent model.
30 Gene therapy has also been employed to
induce ‘cardiac regeneration’, initially attempted by cell transfer strat-
egies only.
5,100 Important recent work has demonstrated that pro-
motion of cardiac repair is also possible by delivery of proteins
such as periostin,
7 thymosin-b4,
9,101 or cyclin A2.
102 Gene transfer
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therapy
83 and may foster this strategy in general.
Independent of such translational applications, regulatory RNA and
gene transfer are indispensable for research. They have helped to
deﬁne the hierarchy of progenitor cells suitable for cardiac
therapy,
103,104 and to discover new important roles for miRNAs in
cellular differentiation.
105 As outlined in Figure 4, the technologies
for RNA- and gene-based therapies are rapidly evolving. New types
of viral vectors and BNPs already have multiple properties required
for in vivo applications and clinical translation. Whereas traditional
nanotechnology has so far been unsuccessful for RNA and gene deliv-
ery to the heart,
106,107 ‘biomimetic’ nanoparticles designed to mimic
key physicochemical properties of virion shells with known cardio-
tropism may in the future develop into an alternative to the current
biological technologies. Recent progress in the ﬁeld suggests that
RNA and gene transfer technology will have a major impact on clinical
practice in the near future, by fundamentally expanding our thera-
peutic repertoire beyond classical drugs and recombinant proteins.
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